2022 article

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1-Defining populations at risk

DeLaforcade, A., Bacek, L., Blais, M.-C., Boyd, C., Brainard, B. M., Chan, D. L., … Sharp, C. (2022, May 2). JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE.

By: A. DeLaforcade*, L. Bacek*, M. Blais*, C. Boyd*, B. Brainard*, D. Chan*, S. Cortellini*, R. Goggs* ...

co-author countries: Australia 🇦🇺 Canada 🇨🇦 United Kingdom of Great Britain and Northern Ireland 🇬🇧 United States of America 🇺🇸
author keywords: arrhythmias; heartworm disease; protein-losing enteropathy; vascular devices
MeSH headings : Adrenocortical Hyperfunction / drug therapy; Adrenocortical Hyperfunction / veterinary; Anemia, Hemolytic, Autoimmune / drug therapy; Anemia, Hemolytic, Autoimmune / veterinary; Animals; Cat Diseases / drug therapy; Cat Diseases / epidemiology; Cats; Consensus; Critical Care; Dirofilariasis; Dog Diseases / drug therapy; Dog Diseases / epidemiology; Dogs; Fibrinolytic Agents / therapeutic use; Protein-Losing Enteropathies / drug therapy; Protein-Losing Enteropathies / veterinary; Risk Factors; Sepsis / veterinary; Thrombosis / veterinary
Source: Web Of Science
Added: May 16, 2022

Abstract Objectives To expand the number of conditions and interventions explored for their associations with thrombosis in the veterinary literature and to provide the basis for prescribing recommendations. Design A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. The revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated in this iteration included heartworm disease (dogs and cats), immune‐mediated hemolytic anemia (cats), protein‐losing nephropathy (cats), protein‐losing enteropathy (dogs and cats), sepsis (cats), hyperadrenocorticism (cats), liver disease (dogs), congenital portosystemic shunts (dogs and cats) and the following interventions: IV catheters (dogs and cats), arterial catheters (dogs and cats), vascular access ports (dogs and cats), extracorporeal circuits (dogs and cats) and transvenous pacemakers (dogs and cats). Results Of the diseases evaluated in this iteration, a high risk for thrombosis was defined as heartworm disease or protein‐losing enteropathy. Low risk for thrombosis was defined as dogs with liver disease, cats with immune‐mediated hemolytic anemia, protein‐losing nephropathy, sepsis, or hyperadrenocorticism. Conclusions Associations with thrombosis are outlined for various conditions and interventions and provide the basis for management recommendations. Numerous knowledge gaps were identified that represent opportunities for future studies.